laquinimod
Sign in to saveAlso known as 5-chloro-4-hydroxy-1-methyl-2-oxo-N-ethyl-N-phenyl-1,2-dihydroquinoline-3-carboxamide
Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS) and Huntington's disease.
Wikidata facts
- Mass
- 356.092770084
Show 2 more facts
- chemical formula
- C₁₉H₁₇ClN₂O₃
- canonical SMILES
- CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1
Sources (2)
via Wikidata · CC0
~1 min read
Article
3 sectionsContents
- See also
- References
- External links
Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS) and Huntington's disease.
Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide.
Connections
lumiliximab
Entity
medication
Entity
pain
Entity
digital object identifier
Entity
chemical formula
Entity
International Standard Serial Number
Entity
major depressive disorder
Entity
central nervous system
Entity
magnetic resonance imaging
Entity
antibody
Entity
multiple sclerosis
Entity
fatigue
Entity
molar mass
Entity
Q180686
Entity
Huntington's disease
Entity
T-lymphocytes
Entity
interferon
Entity
CAS Registry Number
Entity
Q229883
Entity
United States Food and Drug Administration
Entity